Caris Life Sciences, Inc. (CAI) Revenue History
Annual and quarterly revenue from 2013 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CAI Revenue Growth
CAI Revenue Analysis (2013–2025)
As of May 8, 2026, Caris Life Sciences, Inc. (CAI) generated trailing twelve-month (TTM) revenue of $812.0 million. The most recent quarter (Q4 2025) recorded $292.9 million in revenue, up 35.1% sequentially.
Looking at the longer-term picture, CAI's 5-year compound annual growth rate (CAGR) stands at +22.5%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $812.0 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including EXAS (+17.7% YoY), ILMN (+1.2% YoY), and NTRA (+38.2% YoY). Compare CAI vs EXAS →
CAI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CAICurrent | $812M | - | +22.5% | 5.6% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% | |
 NTRA | $1.7B | +38.2% | +41.2% | -13.1% | |
 GH | $982M | +30.4% | +27.9% | -44.5% | |
 FDMT | $85M | +230194.6% | +44.3% | -187.2% |
CAI Historical Revenue Data (2013–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $812.0M | +97.0% | $0 | - | $45.1M | 5.6% |
| 2024 | $412.3M | +34.7% | $178.8M | 43.4% | $-257,122,000 | -62.4% |
| 2023 | $306.1M | +18.4% | $89.3M | 29.2% | $-319,551,000 | -104.4% |
| 2022 | $258.5M | -12.1% | $80.0M | 31.0% | $-315,756,000 | -122.2% |
| 2020 | $294.0M | -29.4% | $184.2M | 62.6% | $139.1M | 47.3% |
| 2019 | $416.5M | -3.6% | $200.5M | 48.1% | $130.3M | 31.3% |
| 2018 | $432.1M | +24.0% | $213.6M | 49.4% | $148.8M | 34.4% |
| 2017 | $348.4M | +18.4% | $169.3M | 48.6% | $105.7M | 30.3% |
| 2016 | $294.4M | +17.9% | $137.5M | 46.7% | $66.0M | 22.4% |
| 2015 | $249.7M | +9.7% | $125.9M | 50.4% | $68.1M | 27.3% |
See CAI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CAI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CAI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCAI — Frequently Asked Questions
Quick answers to the most common questions about buying CAI stock.
Is CAI's revenue growth accelerating or slowing?
CAI TTM revenue: $812M. YoY growth: N/A. 5-year CAGR: +22.5%.
What is CAI's long-term revenue growth rate?
Caris Life Sciences, Inc.'s 5-year revenue CAGR of +22.5% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is CAI's revenue distributed by segment?
CAI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2025 are available for download. Segment mix reveals concentration and diversification trends.